Sodium-glucose co-transporter inhibitors: Mechanisms of action

Tilenka Thynne, Matthew Doogue

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Sodium-glucose co-transporter 2 inhibitors are a new class of drug for the treatment of type 2 diabetes. They lower plasma glucose concentrations by increasing renal excretion of glucose. This class of drugs reduces glucose reabsorption in the kidney and lowers plasma glucose independent of changes in insulin concentrations or peripheral insulin resistance. They have a low risk of hypoglycaemia when used as monotherapy. The known adverse effects of the sodiumglucose co-transporter 2 inhibitors are related to their mechanism of action. They include an increased risk of dehydration and genital and urinary tract infections because of the increase in urinary glucose.

Original languageEnglish
Pages (from-to)14-16
Number of pages3
JournalAustralian Prescriber
Volume37
Issue number1
DOIs
Publication statusPublished - Feb 2014
Externally publishedYes

Keywords

  • Canagliflozin
  • Dapagliflozin
  • Diabetes mellitus type 2
  • Hypoglycaemic drugs
  • Kidney

Fingerprint Dive into the research topics of 'Sodium-glucose co-transporter inhibitors: Mechanisms of action'. Together they form a unique fingerprint.

Cite this